What are the risk factors and components of clinical course associated with progression to restrictive lung disease, and what approaches to treatment can limit this progression?
What is the effectiveness and safety of treatment of the co-morbid condition of asthma with medications known to improve asthma outcomes in individuals without SCD?
What role does venous thromboembolic disease (VTE) play as a disease modulator in Sickle Cell Disease?
What are the risk factors and treatment options for pulmonary hypertension related to diastolic dysfunction in Sickle Cell Disease (SCD)?
Does screening for pulmonary hypertension (PH) of sickle cell disease (SCD) alter disease outcomes?
What is the contribution of airways disease to acute and chronic pulmonary distress?
Do SCD patients with hemodynamics consistent with pulmonary arterial hypertension (PAH) respond to medications designed to treat PAH?
Can we identify biomarkers that can predict sickle cell disease severity?
What are the healthcare implications of sickle cell trait?
What genes are involved in the modulation of phenotype in sickle cell disease?
Does hydroxyurea preserve organ function in patients with sickle cell disease?
Sickle cell treatment centers are located throughout the United States, primarily in urban areas, and play an invaluable role. However, there is a critical need to identify and educate primary care providers who can provide routine and preventive care, but will also know when to consult with/refer to hematologists and other appropriate providers when necessary.
What is the molecular mechanism by which new drug therapies propose to reduce the severity and duration of hospitalization and opioid pain medicines? And how does that impact the course of disease progression?